{"id":1001164,"date":"2026-09-08T08:52:56","date_gmt":"2026-09-08T12:52:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"},"modified":"2026-09-08T08:52:56","modified_gmt":"2026-09-08T12:52:56","slug":"calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","title":{"rendered":"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Sept.  08, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Calidi\u00a0Biotherapeutics Inc. (NYSE American: CLDI)<\/strong>\u00a0(\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28<sup>th<\/sup> Annual Global Investment Conference. The conference is being held on September 14 \u2013 16, 2026 at the Lotte New York Palace Hotel.<\/p>\n<p align=\"left\">Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetings with investors from September 14 \u2013 16. A virtual presentation will be available\u00a0on-demand starting Friday, September 11 at\u00a07:00 AM ET. The presentation will be available for registered attendees via the conference platform.\u00a0<\/p>\n<p align=\"left\">To request a meeting and to register for the conference: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GbsPJTV-IfBAF_Q7zg1EJFFyMKfaee7bn-gIUu5d3oqG-x9MW2g_eOclkH-1nmbx9-LdLL-iPVxLfFOL3t8C-CdzJHjS6Ngh2cd35sN8YOC_YqSJBNYa7dle8OQKUuNVGgfFzfpVc1jta_xGzZF_sw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/hcwevents.com\/annualconference\/<\/a><\/p>\n<p align=\"left\">\n        <strong>About Calidi Biotherapeutics<\/strong>\n      <\/p>\n<p align=\"left\">Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The Company\u2019s proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.<\/p>\n<p align=\"left\">CLD-401, the lead candidate from the RedTail platform, currently in IND-enabling studies, targets metastatic non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the RedTail platform including its novel approach to incorporate in situ T-cell engagers in solid tumors.<\/p>\n<p align=\"left\">Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t0Uhotar8VEm2KMMEaYCIndJ97K5YXX3wViXDjlmk3gl0Q_Hq9z1gfEF070Plu7_Cf3uU2KjPeaP9UVfGVZBKxuy9XQh-4Lt1Q2ZhCUgkcP8vsIOZMKrQEdzhHgvJv6cJeK-2jCWxDgmxW3UfC3NU6c6DsGWK3RLJQHsMHBErY11vTsjSTMjzeW0jTDkzYWy8GP2Nu9E1OkO548ZuQ0n30LljcCVorBMJmB1hGNz_Nw8f8Th5U2dLxxZZZ7ss5bUOMNXyVQKUbSYsm0W8TbNFXhi6bwFGpaX8bBEtMLUhYkWtO8QKhLXs6UQhXO4Z-re8-VSJWZKitmvQ2ZueYsBhesTgjawnUlutPjWQAIadewklDaKHgtS_-MdfUs-DW1B_DgfbMg35AWlf-MvZu-qTZMvBUgym4LsECfmdQftVeVr68qkXmNrurvYVzW7QiO7DH6BKzpTR9uefwuMeZcBXoTe-ZZKQeSPPJ8gOr3tuXA=\" rel=\"nofollow\" target=\"_blank\">www.calidibio.com<\/a>\u00a0or view Calidi\u2019s Corporate Presentation\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZwWhVKJJTPlwdk4gEQSPWHzethV4l_328QxJ0VLIKQ1cIuBa6UZOe-P9KC5cdo714-ouDwbz4C_O7cvvMJehQOgPQoELupVgBmkxS_eupR-Bw1KOL7xTeidSu61c2okVfud1Iyzb1N5upw7BZ5nFmopztVK64EhYV__pxBERnja5tOSw19-Qo_Fa69cC5dfnt5H736zXvybxae5pawVJenZ089pO_a4j1FuDHTQayREjt-oNganyPSPPN0MvxCPir8MV-do-vPo18F4Ly03yBFcbCXgGFRLydnySSA9PbZ3gpYvgjmp-uIPZFs-MiV-i3tqjJnAA95j6E3OgxJX0pE4ag1YdFvFCsOGHTCb9mihHojEwterTY8RQnQhqsA1thPHp1kgsTxLXwdBVrDVweIdDKwE_KV4B6Ad6PrigTPQsz4lkvnERn7USROJk9RNjDar59tuuMr5yhFjGpKJf0cZ20X6JP5qKANQY-OlLOb9PWlKJUWP67IaDrWmoNx1vr4PEShiN57fBXXJoD8wfTRfMhpIHus9Cx0j1ZTBqJz2UbNB_7rg0rtEl0rRQENFzQLBUiJWLxw_MJVkBMcaRJg==\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Investors Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YBfb10jKS5M10iVPNghW96rLmfi4e17Kfhv1E6IJy_SZYTDmoAiAutpgJU0htUKftw7zyEqz9jAL6qoB-3zQcQA6e_7QB9Ee2f8QdMXZB3avZ8CvbVfUjmIc01M8mvkHJ6DIjMKE_OWriIOJTZzRa7Lhna5gs2FGCFype05Cscg-vrqp3CsJoGR8rMTT3HN0gAHxIQ2rdrVSSvzvc_7r640HZPlbuel1VusUE9CO20VqE6FWEhQxqr9U0JcrFJgSJ9BKFK4lIHXJPpy7KFUtGQ==\" rel=\"nofollow\" target=\"_blank\">IR@calidibio.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sWpHxly9v4qpXny07r6fzurTa6LQzaAeULMLbVaz1odFQLDmkRSocBN7tLBwi_eospFg-LC3x0Wn8govfwj5Opz5K0MibkhYD18I9_KuSD43Lb0Rx166-WYRAkmOGDeS_tvbGadnYbQM5yS9HoQ_tbKF8Yd_JVIXM9dUoyH5RvHeK_N_LiQE_SpHbuVnVjD6GF_5uxuX1BLEISTxe4w3p_ka0vwMb1jHoB3szweuqHI3aW6rLYb68Dt4zRXqzfJRpzF2bseRfAG_zmvWowtrQA==\" rel=\"nofollow\" target=\"_blank\">PR@calidibio.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OGI2Nzc2MzQtYzIzMi00OWRhLWE2OGEtMzZjYjA1YWJlZjM4LTEyMDU0MDctMjAyNi0wOS0wOC1lbg==\/tiny\/Calidi-Biotherapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; Calidi\u00a0Biotherapeutics Inc. (NYSE American: CLDI)\u00a0(\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 \u2013 16, 2026 at the Lotte New York Palace Hotel. Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetings with investors from September 14 \u2013 16. A virtual presentation will be available\u00a0on-demand starting Friday, September 11 at\u00a07:00 AM ET. The presentation will be available for registered attendees via the conference platform.\u00a0 To request a meeting and to register for the conference: https:\/\/hcwevents.com\/annualconference\/ About Calidi Biotherapeutics Calidi Biotherapeutics &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1001164","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; Calidi\u00a0Biotherapeutics Inc. (NYSE American: CLDI)\u00a0(\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 \u2013 16, 2026 at the Lotte New York Palace Hotel. Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetings with investors from September 14 \u2013 16. A virtual presentation will be available\u00a0on-demand starting Friday, September 11 at\u00a07:00 AM ET. The presentation will be available for registered attendees via the conference platform.\u00a0 To request a meeting and to register for the conference: https:\/\/hcwevents.com\/annualconference\/ About Calidi Biotherapeutics Calidi Biotherapeutics &hellip; Continue reading &quot;Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T12:52:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference\",\"datePublished\":\"2026-09-08T12:52:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\"},\"wordCount\":297,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\",\"name\":\"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=\",\"datePublished\":\"2026-09-08T12:52:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk","og_description":"SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; Calidi\u00a0Biotherapeutics Inc. (NYSE American: CLDI)\u00a0(\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today announces that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 \u2013 16, 2026 at the Lotte New York Palace Hotel. Eric Poma, Ph.D., Chief Executive Officer of Calidi Biotherapeutics will hold one-on-one meetings with investors from September 14 \u2013 16. A virtual presentation will be available\u00a0on-demand starting Friday, September 11 at\u00a07:00 AM ET. The presentation will be available for registered attendees via the conference platform.\u00a0 To request a meeting and to register for the conference: https:\/\/hcwevents.com\/annualconference\/ About Calidi Biotherapeutics Calidi Biotherapeutics &hellip; Continue reading \"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-08T12:52:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference","datePublished":"2026-09-08T12:52:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"},"wordCount":297,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","name":"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=","datePublished":"2026-09-08T12:52:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTIzNCM3ODE3NjQ0IzIxOTM4NTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1001164"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001164\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1001164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1001164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1001164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}